Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer
Active, not recruiting
Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer
S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
† Study has passed its completion date and status has not been verified in more than two years.